(VIANEWS) – INPOST (INPST.AS), MONTEA (MONT.BR), BAKKAFROST (BAKKA.OL) are the highest sales growth and return on equity stocks on this list.
Here is a list of stocks with an above 5% expected next quarter sales growth, and a 3% or higher return on equity. May these stocks be a good medium-term investment option?
1. INPOST (INPST.AS)
21.7% sales growth and 73.81% return on equity
InPost S.A., together with its subsidiaries, operates as an out-of-home e-commerce enablement platform providing parcel locker services in Europe. It operates through four segments: APM (Automated Parcel Machines), To-Door, Mondial Relay, and International Other. The APM segment focuses on the delivery of parcels to APM. The To-Door segment delivers parcels using door-to-door couriers. The Mondial Relay segment delivers parcels to APM; and operates pick-up drop-off (PUDO) points in France, Spain, Belgium, the Netherlands, Luxembourg, and Portugal. The International Other segment delivers parcels to APM and PUDO points in the United Kingdom and Italy. The company also provides fulfilment services; marketing and IT services; InPost Pay services; and platform for fast-moving consumer goods products through InPost Fresh app. InPost S.A. was founded in 1999 and is headquartered in Luxembourg, Luxembourg.
Earnings Per Share
As for profitability, INPOST has a trailing twelve months EPS of €0.46.
PE Ratio
INPOST has a trailing twelve months price to earnings ratio of 39.48. Meaning, the purchaser of the share is investing €39.48 for every euro of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 73.81%.
Revenue Growth
Year-on-year quarterly revenue growth grew by 22.6%, now sitting on 9.76B for the twelve trailing months.
Growth Estimates Quarters
The company’s growth estimates for the ongoing quarter and the next is 133.3% and 54.5%, respectively.
Sales Growth
INPOST’s sales growth is 21% for the current quarter and 21.7% for the next.
More news about INPOST.
2. MONTEA (MONT.BR)
13.3% sales growth and 11.22% return on equity
Montea NV is a public regulated real estate company under Belgian law (GVV/SIR) that specializes in logistics real estate in Belgium, the Netherlands, France, and Germany. The company is a benchmark player in this market. Montea literally offers its customers the space to grow through versatile and innovative property solutions. In this way, Montea creates value for its shareholders. As of 31/12/2023 the property portfolio represented a total surface of 1,959,242 m², spread across 95 locations. Montea NV has been listed on Euronext Brussels (MONT) and Euronext Paris (MONTP) since the end of 2006.
Earnings Per Share
As for profitability, MONTEA has a trailing twelve months EPS of €8.22.
PE Ratio
MONTEA has a trailing twelve months price to earnings ratio of 8.99. Meaning, the purchaser of the share is investing €8.99 for every euro of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 11.22%.
More news about MONTEA.
3. BAKKAFROST (BAKKA.OL)
11.7% sales growth and 13.83% return on equity
P/F Bakkafrost, together with its subsidiaries, produces and sells salmon products in North America, Western Europe, Eastern Europe, Asia, and internationally. It operates through seven segments: Fishmeal, Fish Oil and Fish Feed; Freshwater FO; Freshwater SCT; Farming FO; Farming SCT; Services; and Sales & Other. The company's products include fresh and frozen whole salmon, fresh and frozen salmon fillets, fresh skin-packed salmon portions, frozen salmon portions and tails, frozen smoked salmon and salmon fillets, frozen salmon bits and pieces, frozen salmon off-cuts and belly flaps, frozen salmon heads, salmon backbones, and salmon skin under the Bakkafrost, 18 ISLANDS, HEIMLAND, BAKKA SALMON, NATIVE HEBRIDEAN, and LOCHLANDER brands. It is also involved in the production and sale of fishmeal, fish oil, and fish feed; production of eggs from breeding self-owned salmon strains; production of smolts; and on-growing of salmon. In addition, the company manages a fleet of farming service vessels; provides fish transportation, treatments, net cleaning, harvesting, freight ans logistical, and heavy marine support services; converts organic waste into biogas, heating, electricity, and fertilizers; produces styrofoam boxes; and optimizes the value creation and retention from the harvested fish. P/F Bakkafrost was founded in 1968 and is headquartered in Glyvrar, Denmark.
Earnings Per Share
As for profitability, BAKKAFROST has a trailing twelve months EPS of kr23.84.
PE Ratio
BAKKAFROST has a trailing twelve months price to earnings ratio of 27.52. Meaning, the purchaser of the share is investing kr27.52 for every norwegian krone of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 13.83%.
Dividend Yield
According to Morningstar, Inc., the next dividend payment is on May 2, 2023, the estimated forward annual dividend rate is 15.63 and the estimated forward annual dividend yield is 2.69%.
Earnings Before Interest, Taxes, Depreciation, and Amortization
BAKKAFROST’s EBITDA is 58.46.
More news about BAKKAFROST.
4. SANOFI (SAN.PA)
7.4% sales growth and 5.82% return on equity
Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products. In addition, it offers poliomyelitis, pertussis, and hib pediatric vaccines; influenza, booster, meningitis, and travel and endemic vaccines, which includes hepatitis A, typhoid, cholera, yellow fever, and rabies vaccines. The company also provides cough, cold, and flu, allergy, and pain care products, as well as physical, mental, and digestive wellness products; and offers products for itching, hydration, aging, cracking, overnight, and specialty skincare needs like eczema. Further, it has a collaboration and license agreement with Exscientia to develop up to 15 novel small-molecule for oncology and immunology; ABL Bio, Inc. to develop ABL301, a treatment for alpha-synucleinopathies; Blackstone Life Sciences to develop pivotal studies and clinical development program; and Seagen Inc. to design, develop, and commercialize antibody-drug conjugates for cancer. Additionally, the company has a collaboration agreement with IGM Biosciences, Inc. to develop, manufacture, and commercialize IgM antibody; Skyhawk Therapeutics, Inc to discover and develop novel small molecules; and Adagene Inc., for the discovery and development of antibody-based therapies. It also has collaborations with Scribe Therapeutics Inc. to develop genome editing technologies; and co-promotion service agreement with Provention Bio, Inc. for the commercialization of teplizumab. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was incorporated in 1994 and is headquartered in Paris, France.
Earnings Per Share
As for profitability, SANOFI has a trailing twelve months EPS of €4.3.
PE Ratio
SANOFI has a trailing twelve months price to earnings ratio of 21.15. Meaning, the purchaser of the share is investing €21.15 for every euro of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 5.82%.
Growth Estimates Quarters
The company’s growth estimates for the ongoing quarter is a negative 5.2% and positive 0.8% for the next.
More news about SANOFI.
5. SPBK1 ØSTFOLD AKE (SOAG.OL)
7.3% sales growth and 12.1% return on equity
SpareBank 1 Østfold Akershus, a savings bank, provides various banking products and services. The company offers savings, operating, tax deduction, deposit, placement, and currency accounts; and savings and investment products. It also provides consumer, construction, repayment, boat, motorcycle, and car loans; operating credit products; bank guarantees; operating credit for agriculture; mortgage products; leasing and factoring services. In addition, the company offers various insurance products, such as vehicle, house and travel, personal, animal, liability, work machine, interruption, condominium, cyber, movable property, commercial building, project, transport, crime, bus, group life, health, leisure accident, occupational injury, accident insurance children, and sick pay insurance products; and pension products. Further, it provides credit, municipal payment, and other bank cards; payment terminal, debt collection, and document collection services; bonds, forwards, and currency options; invoice automatic, eGiro/Cremul, KID invoice, and OCR and eGiro payment services; and mobile and online banking services. SpareBank 1 Østfold Akershus was founded in 1835 and is headquartered in Moss, Norway.
Earnings Per Share
As for profitability, SPBK1 ØSTFOLD AKE has a trailing twelve months EPS of kr38.28.
PE Ratio
SPBK1 ØSTFOLD AKE has a trailing twelve months price to earnings ratio of 9.59. Meaning, the purchaser of the share is investing kr9.59 for every norwegian krone of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 12.1%.
Yearly Top and Bottom Value
SPBK1 ØSTFOLD AKE’s stock is valued at kr367.00 at 17:20 EST, higher than its 52-week high of kr343.00.
Moving Average
SPBK1 ØSTFOLD AKE’s value is higher than its 50-day moving average of kr335.31 and way higher than its 200-day moving average of kr327.11.
Sales Growth
SPBK1 ØSTFOLD AKE’s sales growth for the next quarter is 7.3%.
Volume
Today’s last reported volume for SPBK1 ØSTFOLD AKE is 3 which is 99.16% below its average volume of 358.
More news about SPBK1 ØSTFOLD AKE.
6. IMCD (IMCD.AS)
5.4% sales growth and 16.47% return on equity
IMCD N.V. distributes, markets, and sells specialty chemicals and ingredients in the Netherlands, rest of Europe, the Middle East, Africa, North America, South America, and the Asia-Pacific. The company provides adhesives, core materials, filler reinforcements, flame retardants, masterbatch, modifiers, operating materials, pigments, plasticizers, processing aids, PUR raw materials, rubber elastomers, solvents, stabilizers, thermoplastic elastomers, thermoplastics, thermoplastics, and other additives. It offers actives, UV sunscreens, rheology modifiers, thickeners, surfactants, emulsifiers, emollients, film formers, humectants, waxes, conditioners, hair styling polymers, solvent, solubilizers, pigments, pearls, powders and colorants, opacifiers, pearlizers, preservatives, antioxidants, fragrances, and essential oils. In addition, the company provides functional fillers, pigments, resins, and specialty solvents; taste, texture, nutrition, and function; and abrasives, acids, alkalines, anti-soil redeposition and foam control systems, bio-actives, biocides, bittering and bleaching agents, builders, capsules, chelating agents, concentrates/ready-to-use, corrosion and dye transfer inhibitors, disintegrants, dispersants, emulsifiers, enzymes, fluorinated polymers, oleo chemicals, optical brighteners, perfumes, dyes, phosphates, plasticisers, proteins, rheology modifiers and thickeners, silicones, solvents/diluents, TAED, UV-filters, and waxes. Further, it offers base oils; lubricants addictive; lubricants finished fluids; fuel additives; solvents, degreasers, and fuel compounds; and upstream, midstream, and downstream oil, gas, and energy. IMCD N.V. was founded in 1995 and is headquartered in Rotterdam, the Netherlands.
Earnings Per Share
As for profitability, IMCD has a trailing twelve months EPS of €4.93.
PE Ratio
IMCD has a trailing twelve months price to earnings ratio of 31.33. Meaning, the purchaser of the share is investing €31.33 for every euro of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 16.47%.
Dividend Yield
As maintained by Morningstar, Inc., the next dividend payment is on May 16, 2024, the estimated forward annual dividend rate is 2.24 and the estimated forward annual dividend yield is 1.47%.
Yearly Top and Bottom Value
IMCD’s stock is valued at €154.45 at 17:20 EST, below its 52-week high of €169.05 and way above its 52-week low of €109.05.
More news about IMCD.
